Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012 (2012), Article ID 728461, 13 pages
http://dx.doi.org/10.1155/2012/728461
Review Article

New Insights into the Role of Peroxisome Proliferator-Activated Receptors in Regulating the Inflammatory Response after Tissue Injury

1Department of Orthopaedic Surgery, University of Colorado Denver, School of Medicine, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, USA
2Department of Trauma and Reconstructive Surgery, University Hospital Ulm, Steinhövelstraße 9, D-89075 Ulm, Germany
3Department of Neurosurgery, University of Colorado Denver, School of Medicine, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, USA

Received 13 August 2011; Accepted 4 November 2011

Academic Editor: John P. Vanden Heuvel

Copyright © 2012 Miriam D. Neher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Kauvar and C. E. Wade, “The epidemiology and modern management of traumatic hemorrhage: US and international perspectives,” Critical Care, vol. 9, supplement 5, pp. S1–S9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. E. Bianchi and A. A. Manfredi, “Dangers in and out,” Science, vol. 323, no. 5922, pp. 1683–1684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. P. F. Stahel, W. R. Smith, and E. E. Moore, “Role of biological modifiers regulating the immune response after trauma,” Injury, vol. 38, no. 12, pp. 1409–1422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Keel and O. Trentz, “Pathophysiology of polytrauma,” Injury, vol. 36, no. 6, pp. 691–709, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Cuzzocrea, “Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury,” Vascular Pharmacology, vol. 41, no. 6, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. P. F. Stahel, W. R. Smith, J. Bruchis, and C. H. Rabb, “Peroxisome proliferator-activated receptors: “Key” regulators of neuroinflammation after traumatic brain injury,” PPAR Research, vol. 2008, Article ID 538141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Giaginis, G. Tsourouflis, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury,” Current Molecular Medicine, vol. 8, no. 6, pp. 562–579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Von Knethen, M. Soller, and B. Brüne, “Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 55, no. 1, pp. 19–25, 2007. View at Publisher · View at Google Scholar
  9. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Staels and J. C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Abdelrahman, A. Sivarajah, and C. Thiemermann, “Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock,” Cardiovascular Research, vol. 65, no. 4, pp. 772–781, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. van Neerven and J. Mey, “RAR/RXR and PPAR/RXR signaling in spinal cord injury,” PPAR Research, vol. 2007, Article ID 29275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  15. L. Michalik and W. Wahli, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Youssef and M. Badr, “Peroxisome proliferator-activated receptors and cancer: challenges and opportunities,” British Journal of Pharmacology, vol. 164, no. 1, pp. 68–82, 2011. View at Publisher · View at Google Scholar
  17. J. Plutzky, “The PPAR-RXR transcriptional complex in the vasculature: energy in the balance,” Circulation Research, vol. 108, no. 8, pp. 1002–1016, 2011. View at Publisher · View at Google Scholar
  18. A. Montagner, G. Rando, G. Degueurce, N. Leuenberger, L. Michalik, and W. Wahli, “New insights into the role of PPARs,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 85, no. 5, pp. 235–243, 2011. View at Publisher · View at Google Scholar
  19. A. Yessoufou and W. Wahli, “Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels,” Swiss Medical Weekly, vol. 140, Article ID w13071, pp. 4–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. M. McMillan and G. M. Teasdale, “Death rate is increased for at least 7 years after head injury: a prospective study,” Brain, vol. 130, part 10, pp. 2520–2527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. O. I. Schmidt, C. E. Heyde, W. Ertel, and P. F. Stahel, “Closed head injury—an inflammatory disease?” Brain Research Reviews, vol. 48, no. 2, pp. 388–399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Gaetz, “The neurophysiology of brain injury,” Clinical Neurophysiology, vol. 115, no. 1, pp. 4–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. J. Bright, S. Kanakasabai, W. Chearwae, and S. Chakraborty, “PPAR regulation of inflammatory signaling in CNS diseases,” PPAR Research, vol. 2008, Article ID 658520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Kapadia, J. H. Yi, and R. Vemuganti, “Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists,” Frontiers in Bioscience, vol. 13, no. 5, pp. 1813–1826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. E. Cullingford, K. Bhakoo, S. Peuchen, C. T. Dolphin, R. Patel, and J. B. Clark, “Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system,” Journal of Neurochemistry, vol. 70, no. 4, pp. 1366–1375, 1998. View at Google Scholar
  26. S. Moreno, S. Farioli-vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Yi, S. W. Park, N. Brooks, B. T. Lang, and R. Vemuganti, “PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms,” Brain Research, vol. 1244, pp. 164–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Almad and D. M. McTigue, “Chronic expression of PPAR-δ by oligodendrocyte lineage cells in the injured rat spinal cord,” Journal of Comparative Neurology, vol. 518, no. 6, pp. 785–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Feng, Y. Zhang, and G. Chen, “Cortical expression of peroxisome proliferator-activated receptor-α after human brain contusion,” Journal of International Medical Research, vol. 36, no. 4, pp. 783–791, 2008. View at Google Scholar · View at Scopus
  30. R. Bordet, P. Gelé, P. Duriez, and J. C. Fruchart, “PPARs: a new target for neuroprotection,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 3, pp. 285–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Qi, A. Jacob, P. Wang, and R. Wu, “Peroxisome proliferator activated receptor-γ and traumatic brain injury,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 4, pp. 283–292, 2010. View at Google Scholar · View at Scopus
  32. R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, part 6, pp. 1341–1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Bernando and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Hyong, V. Jadhav, S. Lee et al., “Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents,” Brain Research, vol. 1215, no. C, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Collino, M. Aragno, R. Mastrocola et al., “Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. X. R. Chen, V. C. Besson, B. Palmier, Y. Garcia, M. Plotkine, and C. Marchand-Leroux, “Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury,” Journal of Neurotrauma, vol. 24, no. 7, pp. 1119–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Zhao, Y. Zhang, R. Strong, J. C. Grotta, and J. Aronowski, “15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-γ, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 6, pp. 811–820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Genovese, E. Mazzon, R. Di Paola et al., “Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma,” Experimental Neurology, vol. 194, no. 1, pp. 267–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Genovese, E. Esposito, E. Mazzon et al., “PPAR-α modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma,” Pharmacological Research, vol. 59, no. 5, pp. 338–350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Esposito and S. Cuzzocrea, “Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury,” Expert Opinion on Therapeutic Targets, vol. 15, no. 8, pp. 943–959, 2011. View at Publisher · View at Google Scholar
  41. V. C. Besson, X. R. Chen, M. Plotkine, and C. Marchand-Verrecchia, “Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury,” Neuroscience Letters, vol. 388, no. 1, pp. 7–12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. R. C. Xiao, V. C. Besson, T. Beziaud, M. Plotkine, and C. Marchand-Leroux, “Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor α agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, on experimental traumatic brain injury,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 3, pp. 966–974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. D. M. McTigue, “Potential therapeutic targets for PPARγ after spinal cord injury,” PPAR Research, vol. 2008, Article ID 517162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Sauerbeck, J. Gao, R. Readnower et al., “Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury,” Experimental Neurology, vol. 227, no. 1, pp. 128–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. D. Semple and L. J. Noble-Haeusslein, “Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors,” Experimental Neurology, vol. 229, no. 2, pp. 195–197, 2011. View at Publisher · View at Google Scholar
  46. Q. Zhang, W. Hu, B. Meng, and T. Tang, “PPARγ agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats,” Neurological Research, vol. 32, no. 8, pp. 852–859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. S. W. Park, J. H. Yi, G. Miranpuri et al., “Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1002–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. D. M. McTigue, R. Tripathi, P. Wei, and A. T. Lash, “The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury,” Experimental Neurology, vol. 205, no. 2, pp. 396–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. Q. Zhang, C. Huang, T. Tang, Q. Shi, and H. Yang, “Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferator-activated receptor-γ following spinal cord injury,” Neurosciences, vol. 16, no. 1, pp. 46–52, 2011. View at Google Scholar
  50. R. Mechoulam, D. Panikashvili, and E. Shohami, “Cannabinoids and brain injury: therapeutic implications,” Trends in Molecular Medicine, vol. 8, no. 2, pp. 58–61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Mechoulam and E. Shohami, “Endocannabinoids and traumatic brain injury,” Molecular Neurobiology, vol. 36, no. 1, pp. 68–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Bayir, R. S. B. Clark, and P. M. Kochanek, “Promising strategies to minimize secondary brain injury after head trauma,” Critical Care Medicine, vol. 31, no. 1, pp. S112–S117, 2003. View at Google Scholar · View at Scopus
  53. Y. Sun and A. Bennett, “Cannabinoids: a new group of agonists of PPARs,” PPAR Research, vol. 2007, Article ID 23513, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Panikashvili, C. Simeonidou, S. Ben-Shabat et al., “An endogenous cannabinoid (2-AG) is neuroprotective after brain injury,” Nature, vol. 413, no. 6855, pp. 527–531, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Gallily, A. Breuer, and R. Mechoulam, “2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice,” European Journal of Pharmacology, vol. 406, no. 1, pp. R5–R7, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Shohami, M. Novikov, and R. Mechoulam, “A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat,” Journal of Neurotrauma, vol. 10, no. 2, pp. 109–119, 1993. View at Google Scholar · View at Scopus
  57. E. Shohami, R. Gallily, R. Mechoulam, R. Bass, and T. Ben-Hur, “Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant,” Journal of Neuroimmunology, vol. 72, no. 2, pp. 169–177, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Fu, S. Gaetani, F. Oveisi et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α,” Nature, vol. 425, no. 6953, pp. 90–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. S. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of Δ9- tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005. View at Publisher · View at Google Scholar
  61. N. Knoller, L. Levi, I. Shoshan et al., “Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial,” Critical Care Medicine, vol. 30, no. 3, pp. 548–554, 2002. View at Google Scholar · View at Scopus
  62. R. K. Narayan, M. E. Michel, B. Ansell et al., “Clinical trials in head injury,” Journal of Neurotrauma, vol. 19, no. 5, pp. 503–557, 2002. View at Google Scholar · View at Scopus
  63. G. R. Heyndrickx, “Early reperfusion phenomena,” Seminars in Cardiothoracic and Vascular Anesthesia, vol. 10, no. 3, pp. 236–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Matsuyama, R. Yoshimura, Y. Kawahito et al., “Relationship between peroxisome proliferator-activated receptor-γ and renal ischemia-reperfusion injury,” Molecular Medicine Reports, vol. 1, no. 4, pp. 499–503, 2008. View at Google Scholar · View at Scopus
  65. R. Yoshimura, M. Matsuyama, Y. Segawa et al., “Study of peroxisome proliferator-activated receptor (PPAR)-γ in renal ischemia-reperfusion injury,” Transplantation Proceedings, vol. 36, no. 7, pp. 1946–1948, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. C. H. Lee, O. K. Park, K. Y. Yoo et al., “The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage,” Journal of the Neurological Sciences, vol. 300, no. 1-2, pp. 120–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Cuzzocrea, B. Pisano, L. Dugo et al., “Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut,” British Journal of Pharmacology, vol. 140, no. 2, pp. 366–376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. P. K. Chatterjee, N. S. A. Patel, S. Cuzzocrea et al., “The cyclopentenone prostaglandin 15-deoxy-Δ12,14- prostaglandin J2 ameliorates ischemic acute renal failure,” Cardiovascular Research, vol. 61, no. 3, pp. 630–643, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Okada, S. F. Yan, and D. J. Pinsky, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets,” FASEB Journal, vol. 16, no. 14, pp. 1861–1868, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. Q. Guo, G. Wang, and S. Namura, “Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 1, pp. 70–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Cuzzocrea, R. Di Paola, E. Mazzon, T. Genovese, C. Muià, and A. P. Caputi, “WY 14643, a potent exogenous PPAR-α ligand, reduces intestinal injury associated with splanchnic artery occlusion shock,” Shock, vol. 22, no. 4, pp. 340–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar · View at Scopus
  74. K. Ito, J. Shimada, D. Kato et al., “Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in rats,” European Journal of Cardio-thoracic Surgery, vol. 25, no. 4, pp. 530–536, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Honda, K. Kaikita, K. Tsujita et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 5, pp. 915–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Luo, W. Yin, A. P. Signore et al., “Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone,” Journal of Neurochemistry, vol. 97, no. 2, pp. 435–448, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Sivarajah, P. K. Chatterjee, N. S. A. Patel et al., “Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury,” American Journal of Nephrology, vol. 23, no. 4, pp. 267–276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Villegas, A. R. Martín, W. Toma, and C. Alarcón de la Lastra, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation,” European Journal of Pharmacology, vol. 505, no. 1–3, pp. 195–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Doi, T. Masaki, T. Arakawa et al., “Protective effects of peroxisome proliferator-activated receptor γ ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury,” Transplantation, vol. 84, no. 2, pp. 207–213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Di Paola, E. Esposito, E. Mazzon, I. Paterniti, M. Galuppo, and S. Cuzzocrea, “GW0742, a selective PPAR-β/δ agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury,” Journal of Leukocyte Biology, vol. 88, no. 2, pp. 291–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Li, K. Chen, N. Sinha et al., “The effects of PPAR-γ ligand pioglitazone on platelet aggregation and arterial thrombus formation,” Cardiovascular Research, vol. 65, no. 4, pp. 907–912, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. M. S. Paller, “The cell biology of reperfusion injury in the kidney,” Journal of Investigative Medicine, vol. 42, no. 4, pp. 632–639, 1994. View at Google Scholar · View at Scopus
  83. N. S. A. Patel, R. di Paola, E. Mazzon, D. Britti, C. Thiemermann, and S. Cuzzocrea, “Peroxisome proliferator-activated receptor-α contributes to the resolution of inflammation after renal ischemia/reperfusion injury,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 2, pp. 635–643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Collino, E. Benetti, G. Miglio et al., “Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats,” Free Radical Biology and Medicine, vol. 50, no. 2, pp. 345–353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Letavernier, J. Perez, E. Joye et al., “Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2395–2402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. H. H. Chen, T. W. Chen, and H. Lin, “Prostacyclin-induced peroxisome proliferator-activated receptor-α translocation attenuates NF-κB and TNF-α activation after renal ischemia-reperfusion injury,” American Journal of Physiology—Renal Physiology, vol. 297, no. 4, pp. F1109–F1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D. Crew, and A. D. Proia, “Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure,” American Journal of Physiology—Renal Physiology, vol. 278, no. 4, pp. F667–F675, 2000. View at Google Scholar · View at Scopus
  88. S. Li, K. K. Nagothu, V. Desai et al., “Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-α in mice confers protection during acute kidney injury,” Kidney International, vol. 76, no. 10, pp. 1049–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. R. C. King, O. A. R. Binns, F. Rodriguez et al., “Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation,” Annals of Thoracic Surgery, vol. 69, no. 6, pp. 1681–1685, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. M. S. Cappell, “Intestinal (mesenteric) vasculopathy II. Ischemic colitis and chronic mesenteric ischemia,” Gastroenterology Clinics of North America, vol. 27, no. 4, pp. 827–860, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Ichikawa, Y. Naito, T. Takagi, N. Tomatsuri, N. Yoshida, and T. Yoshikawa, “A specific peroxisome proliferator-induced receptor-γ (PPAR-γ) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats,” Redox Report, vol. 7, no. 5, pp. 343–346, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Sato, F. A. Moore, B. C. Kone et al., “Differential induction of PPAR-γ by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 290, no. 4, pp. G616–G623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Ban and R. A. Kozar, “Enteral glutamine: a novel mediator of PPARγ in the postischemic gut,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 595–599, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. G. J. Hankey and C. P. Warlow, “Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations,” Lancet, vol. 354, no. 9188, pp. 1457–1463, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. Z. Fatehi-Hassanabad and R. A. Tasker, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation confers functional neuroprotection in global ischemia,” Neurotoxicity Research, vol. 19, no. 3, pp. 462–471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. H. B. Rubins, J. Davenport, V. Babikian et al., “Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol the veterans affairs HDL intervention trial (VA-HIT),” Circulation, vol. 103, no. 23, pp. 2828–2833, 2001. View at Google Scholar · View at Scopus
  97. A. Iwashita, Y. Muramatsu, T. Yamazaki et al., “Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1087–1096, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. N. A. Victor, E. W. Wanderi, J. Gamboa et al., “Altered PPARγ expression and activation after transient focal ischemia in rats,” European Journal of Neuroscience, vol. 24, no. 6, pp. 1653–1663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. T. N. Lin, W. M. Cheung, J. S. Wu et al., “15d-prostaglandin J2 protects brain from ischemia-reperfusion injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 481–487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Sundararajan, J. L. Gamboa, N. A. Victor, E. W. Wanderi, W. D. Lust, and G. E. Landreth, “Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia,” Neuroscience, vol. 130, no. 3, pp. 685–696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Shimazu, I. Inoue, N. Araki et al., “A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia,” Stroke, vol. 36, no. 2, pp. 353–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Gamboa, D. A. Blankenship, J. P. Niemi et al., “Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion,” Neuroscience, vol. 170, no. 3, pp. 846–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Kasahara, A. Taguchi, H. Uno et al., “Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia,” Brain Research, vol. 1340, no. C, pp. 70–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. J. M. Kaplan, J. A. Cook, P. W. Hake, M. O'Connor, T. J. Burroughs, and B. Zingarelli, “15-Deoxy-Δ12,14-prostaglandin J2 (15D-PGJ 2), a peroxisome proliferator activated receptor γ ligand, reduces tissue leukosequestration and mortality in endotoxic shock,” Shock, vol. 24, no. 1, pp. 59–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Zingarelli, R. Chima, M. O'Connor, G. Piraino, A. Denenberg, and P. W. Hake, “Liver apoptosis is age dependent and is reduced by activation of peroxisome proliferator-activated receptor-γ in hemorrhagic shock,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 298, no. 1, pp. G133–G141, 2010. View at Publisher · View at Google Scholar
  106. A. Kapoor, Y. Shintani, M. Collino et al., “Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 12, pp. 1506–1515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Wiel, G. Lebuffe, E. Robin et al., “Pretreatment with peroxysome proliferator-activated receptor α agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock,” Intensive Care Medicine, vol. 31, no. 9, pp. 1269–1279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Soller, A. Tautenhahn, B. Brüne et al., “Peroxisome proliferator-activated receptor γ contributes to T lymphocyte apoptosis during sepsis,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 235–243, 2006. View at Publisher · View at Google Scholar
  109. R. C. Reddy, V. R. Narala, V. G. Keshamouni, J. E. Milam, M. W. Newstead, and T. J. Standiford, “Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-γ,” Blood, vol. 112, no. 10, pp. 4250–4258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. W. T. Wu, C. C. Lee, C. J. Lee, Y. M. Subeq, R. P. Lee, and B. G. Hsu, “Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats,” Biological Research for Nursing, vol. 13, no. 1, pp. 38–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Abdelrahman, M. Collin, and C. Thiemermann, “The peroxisome proliferator-activated receptor-γ ligand 15-deoxy Δ12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock,” Shock, vol. 22, no. 6, pp. 555–561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. R. S. Chima, P. W. Hake, G. Piraino, P. Mangeshkar, A. Denenberg, and B. Zingarelli, “Ciglitazone ameliorates lung inflammation by modulating the inhibitor κb protein kinase/nuclear factor-κB pathway after hemorrhagic shock,” Critical Care Medicine, vol. 36, no. 10, pp. 2849–2857, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. R. S. Chima, P. W. Hake, G. Piraino, P. Mangeshkar, M. O'Connor, and B. Zingarelli, “Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 1, pp. 1–9, 2010. View at Google Scholar · View at Scopus
  114. B. Zingarelli, M. Sheehan, P. W. Hake, M. O'Connor, A. Denenberg, and J. A. Cook, “Peroxisome proliferator activator receptor-γ ligands, 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways,” Journal of Immunology, vol. 171, no. 12, pp. 6827–6837, 2003. View at Google Scholar · View at Scopus
  115. B. Zingarelli, G. Piraino, P. W. Hake et al., “Peroxisome proliferator-activated receptor δ regulates inflammation via NF-κB signaling in polymicrobial sepsis,” American Journal of Pathology, vol. 177, no. 4, pp. 1834–1847, 2010. View at Publisher · View at Google Scholar
  116. S. Cuzzocrea, B. Pisano, L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice,” Critical Care Medicine, vol. 32, no. 2, pp. 457–466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Galuppo, R. Di Paola, E. Mazzon et al., “Role of PPAR-δ in the development of zymosan-induced multiple organ failure: an experiment mice study,” Journal of Inflammation, vol. 7, article 12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. D. F. Steiner, D. Cunningham, L. Spigelman, and B. Aten, “Insulin biosynthesis: evidence for a precursor,” Science, vol. 157, no. 3789, pp. 697–700, 1967. View at Google Scholar · View at Scopus
  119. N. M. Al-Rasheed, R. S. Chanai, R. J. Baines, G. B. Willars, and N. J. Brunskill, “Ligand-independent activation of peroxisome proliferator-activated receptor-γ by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity,” Journal of Biological Chemistry, vol. 279, no. 48, pp. 49747–49754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. L. H. Young, Y. Ikeda, R. Scalia, and A. M. Lefer, “C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 279, no. 4, pp. H1453–H1459, 2000. View at Google Scholar · View at Scopus
  121. M. G. Vish, P. Mangeshkar, G. Piraino et al., “Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice,” Critical Care Medicine, vol. 35, no. 5, pp. 1348–1355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. R. S. Chima, T. LaMontagne, G. Piraino, P. W. Hake, A. Denenberg, and B. Zingarelli, “C-peptide, a novel inhibitor of lung inflammation following hemorrhagic shock,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 300, no. 5, pp. L730–L739, 2011. View at Publisher · View at Google Scholar
  123. R. Wu, M. Zhou, and P. Wang, “Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-α in macrophage cell line and rat Kupffer cells,” Regulatory Peptides, vol. 112, no. 1–3, pp. 19–26, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Miksa, R. Wu, X. Cui et al., “Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-γ,” Journal of Immunology, vol. 179, no. 9, pp. 6263–6272, 2007. View at Google Scholar · View at Scopus
  125. M. E. Greene, B. Blumberg, O. W. McBride et al., “isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995. View at Google Scholar · View at Scopus
  126. M. V. Schmidt, P. Paulus, A. M. Kuhn et al., “Peroxisome proliferator-activated receptor g-induced T cell apoptosis reduces survival during polymicrobial sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 64–74, 2011. View at Publisher · View at Google Scholar
  127. L. Michalik, B. Desvergne, N. S. Tan et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice,” Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Dubrac and M. Schmuth, “PPAR-alpha in cutaneous inflammation,” Dermato-Endocrinology, vol. 3, no. 1, pp. 23–26, 2011. View at Publisher · View at Google Scholar
  129. G. Icre, W. Wahli, and L. Michalik, “Functions of the peroxisome proliferator-activated receptor (PPAR) α and β in skin homeostasis, epithelial repair, and morphogenesis,” Journal of Investigative Dermatology Symposium Proceedings, vol. 11, no. 1, pp. 30–35, 2006. View at Publisher · View at Google Scholar
  130. N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPARβ/δ in keratinocyte response to inflammation,” Genes and Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar · View at Scopus
  131. N. Di-Po, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” Molecular Cell, vol. 10, no. 4, pp. 721–733, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. S. T. Nguan, G. Icre, A. Montagner, B. Bordier-Ten Heggeler, W. Wahli, and L. Michalik, “The nuclear hormone receptor peroxisome proliferator-activated receptor β/δ potentiates cell chemotactism, polarization, and migration,” Molecular and Cellular Biology, vol. 27, no. 20, pp. 7161–7175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. N. S. Tan, L. Michalik, N. Di-Poï et al., “Essential role of Smad3 in the inhibition of inflammation-induced PPARβ/δ expression,” EMBO Journal, vol. 23, no. 21, pp. 4211–4221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Genetic- or transforming growth factor-β1-induced changes in epidermal peroxisome proliferator-activated receptor β/δ expression dictate wound repair kinetics,” Journal of Biological Chemistry, vol. 280, no. 18, pp. 18163–18170, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. H. C. Chong, M. J. Tan, V. Philippe et al., “Regulation of epithelial-mesenchymal IL-1 signaling by PPARβ/δ is essential for skin homeostasis and wound healing,” Journal of Cell Biology, vol. 184, no. 6, pp. 817–831, 2009. View at Publisher · View at Google Scholar · View at Scopus